The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2021 | Efficacy of datopotamab deruxtecan, a TROP2 ADC, in aNSCLC
Alex Spira, MD, PhD, FACP, Virginia Cancer Specialists, Fairfax, VA, shares the updated results of a trial of datopotamab deruxtecan (Dato-DXd; DS-1062) use in non-small cell lung cancer (NSCLC), conducted as part of the Phase I TROPION-PanTumor01 study (NCT03401385). Dato-DXd is an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) which is overexpressed in NSCLC. In total, 133 patients with advanced/metastatic relapsed/refractory (R/R) NSCLC were enrolled and treated at various dose levels to determine the maximum tolerated dose. A promising complete/partial response rate and dose control rate were achieved, and the toxicity was manageable. Efficacy and safety considerations established the recommended future dose as 6mg/kg. This interview took place during the IASLC World Conference on Lung Cancer (WCLC) virtual meeting 2021.
